Klaus Stöckemann, PhD MBA
Co-Founder & Managing Partner at Peppermint VenturePartners
Startupbootcamp Digital Health Berlin Mentor
Dr. Stöckemann is the co-founder of Peppermint Venture Partners and one of the managing partners in the Charité Biomedical Fund. As a former General Partner in the international Healthcare Venture Team of 3i, he is a highly experienced venture capitalist. He has been active for more than 10 year in the Venture Capital industry and was responsible for more than 12 investments during his tenure at 3i. His track record at 3i includes the IPO of companies like Epigenomics, Jerini and Santhera as well as the trade sales of Evotec Neuroscience, Amaxa and Elbion. Dr. Stöckemann has been board member of Combinature, Epigenomics, Jerini, Amaxa, Immatics as well as IntelliDx and Zonare in the US. He is currently Chairman of the boards of Humedics and Hematris. Prior to joining 3i, Dr. Stöckemann held leading positions in R&D and Business Development with large Pharma companies like Schering AG and ASTA Medica (a Degussa & Hüls group company). He holds a Ph.D in Biology and Pharmacology from the University of Mainz, as well as a MBA from WHU / Kellogg Northwestern University in the US.